RU58841 (PSK‑3841 / HMR‑3841)
Experimental skin-applied hair loss compound: mainly studied in animals, unproven in humans and not approved as a medicine.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is RU58841 (PSK-3841 / HMR-3841)?
RU58841 is an experimental compound that was designed to be applied to the skin against hair loss and acne. It has never been approved as a medicine anywhere. It is sold as a research chemical, with no official oversight or quality control, so its purity and composition are unverified. Bodybuilders also show interest in it as a way to prevent hair loss.
It does not stop DHT (dihydrotestosterone, a strong male hormone) from forming, as finasteride does. Instead it is thought to take the place of the hormone in the hair follicle, so that in theory the hormone cannot thin the hairs. This has mainly been studied in animals; its effect and safety in people are unproven. It should be strictly avoided in pregnancy and while breastfeeding, because a substance that blocks the action of male hormones could in theory harm the development of a male baby. In competitive sport it counts as banned.
Mechanism
Peripheral non-steroidal AR antagonist (NOT a 5AR inhibitor!) – scalp follicular AR binding blockade
Half-life
Topical minimal systemic absorption (claim), effect ~24 h
Onset
Scalp AR blockade immediate, hair stabilization 3-6 months (in vivo data sparse)
Legal status
Not approved; research chemical; considered banned in sport
RU-58841 is described in anecdotal accounts as a solid and accessible topical anti-androgen. Community members report that users running heavy AAS cycles often notice hair shedding subsiding when applying it topically to affected areas. It is generally regarded as an effective first-line topical option compared to systemic DHT blockers, since DHT serves physiological roles and broad pharmacological suppression carries tradeoffs. Some accounts now prefer pyrilutamide (Topilutumide) over RU-58841, citing potentially lower systemic risk and comparable efficacy. RU-58841 is intended for topical application only and should not be ingested orally. Overall, it remains one of the more established topical anti-androgens in community use for managing AAS-related hair loss.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C . Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques.. Endocrine.
De Brouwer B, Tételin C, Leroy T, Bonfils A, Van Neste D . A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts in nude mice.. Br J Dermatol.
Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis ChC, Blume-Peytavi U, Schäfer-Korting M . RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia.. Pharmazie.
Dhurat R, Sharma A, Rudnicka L, Kanti V, Vañó-Galván S, Pirmez R, Sinclair R, Doolan B, Tosti A . 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.. Dermatol Ther.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Systemic feminizing effects with meaningful absorption: gynecomastia, reduced libido, erectile dysfunction, deteriorating sperm quality (the documented reason for the 1996 Phase II trial termination).
- Local scalp irritation, itching, redness and contact dermatitis, mainly from the ethanol/propylene glycol vehicle (the most common, well-documented local effect).
- NO long-term (6+ months) safety data: the endocrine and reproductive risks of chronic absorption are unknown because clinical development stopped at Phase II.
- UGL/research-chemical sourcing risks: purity often <90%, unstable solution (potency <50% after 6 months at room temperature), vehicle-contamination allergy – the actual active content is not guaranteed.
- Systemic AR blockade may suppress the anabolic effect of a concurrent AAS or SARM cycle if the compound is absorbed (receptor-level antagonism, not a mechanism conflict).
- Mood symptoms: the Phase II monitoring protocol explicitly tracked IIEF-5 (sexual function) and PHQ-9 (depression), pointing to possible psychological complaints alongside sexual dysfunction.
Contraindications · 7
- Contact with a pregnant partner: with systemic absorption the AR antagonist could theoretically disrupt fetal male sexual development – avoid when a partner is pregnant or planning pregnancy.
- Fertility planning / active conception intent: not recommended for users planning children due to documented sperm-quality deterioration and sexual dysfunction.
- Not indicated for prophylactic use in those not predisposed to AGA: with research-chemical status and absent safety evidence the risk-benefit balance is unjustifiable.
- Topical only: NEVER take orally – the compound is intended for the scalp alone; ingestion drastically raises the risk of systemic AR blockade and feminizing effects.
- Long-term chronic use (>12 months): in vivo safety data are missing and Phase II was halted precisely over systemic side effects – chronic use is not supported.
- Prohibited for competitive athletes: banned by WADA under S1 (Other Anabolic Agents) as an AR modulator, both in and out of competition.
- Damaged/inflamed scalp or ethanol/propylene glycol sensitivity: the vehicle can trigger contact dermatitis and increases systemic absorption when the skin barrier is compromised.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques.
Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C
A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts in nude mice.
De Brouwer B, Tételin C, Leroy T, Bonfils A, Van Neste D
RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia.
Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis ChC, Blume-Peytavi U, Schäfer-Korting M
5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
Dhurat R, Sharma A, Rudnicka L, Kanti V, Vañó-Galván S, Pirmez R, Sinclair R, Doolan B, Tosti A
Telegram
Have a question about RU58841 (PSK‑3841 / HMR‑3841)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.
